Akamara Therapeutics

Founders: Shiladitya Sengupta

About: Akamara is a biotechnology company pioneering exciting new types of cancer treatment by developing supramolecular structures that target B-cell immunotherapy. With a lead molecule focused on triple negative breast cancer, Akamara aims to adopt a multidisciplinary approach to research with the ultimate goal of a paradigm shift in cancer care.

Why we invested: Immuno-oncology is rapidly transforming the way cancer is treated, and Akamara’s focus on B-cells will set it apart. We believe B-cells could become very important complements to T-cells, which are already demonstrating efficacy only in certain patient populations.